Richard D. Carvajal, MD: You presented nice work trying to tease out the potential confounding effects of post-progression therapies.
Video Reports
Uveal Melanoma: Patient Candidacy for Tebentafusp
Richard D. Carvajal, MD: We have the 202 [IMCgp100-202] study, which was basically untreated patients, a clear survival advantage.
Tebentafusp for Uveal Melanoma: Cytokine Release Syndrome
Richard D. Carvajal, MD: The other big category of toxicity is the cytokine release syndrome [CRS]-type symptoms.
Uveal Melanoma: Current Treatment Approaches
Richard D. Carvajal, MD: Hello, my name is Richard Carvajal. I’m a medical oncologist at Columbia University Irving Medical Center in New York, New York.